Previous 10 | Next 10 |
ADMA Biologics (NASDAQ: ADMA ) +46% as FDA approves ADMA Biologics' ASCENIV. More news on: ADMA Biologics, Inc., Sangamo Therapeutics, Inc., Riot Blockchain, Inc., Stocks on the move, Read more ...
AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019 at 2:10 p.m. BST. A live webcast of the presentation can be accessed by visitin...
AVEO Pharmaceuticals (NASDAQ: AVEO ) is up 22.5% on heavy volume after hours following positive results from a trial addressing acute myeloid leukemia. More news on: AVEO Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
- Data presented during poster session at the AACR 2019 Annual Meeting - AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced results from an investigator-sponsored Phase Ib expansion cohort of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory anti...
Biopharmaceutical company AVEO Pharmaceuticals (NASDAQ:AVEO) is among the trending tickers of the day on Yahoo Finance, increasing by 28.49% by 3:00 pm EST following rumors that AstraZeneca PLC (NYSE:AZN) will acquire the company in Q2 2019. According to Seeking Alpha, representati...
CORAL GABLES, FL/ ACCESSWIRE / March 27, 2019 / The future of the biotech stock is predicated on the belief that the biotech sector is aptly prepared to develop innovative treatment options for patients in need. Medical experts and care professionals are faced with an increasing global pop...
NEW YORK, NY / ACCESSWIRE / March 26, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bron...
AVEO Pharmaceuticals (NASDAQ: AVEO ): Q4 GAAP EPS of -$0.03. More news on: AVEO Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2018 and provided a business update. “The results of TIVO-3, presented in February at the 2019 ASCO GU Symposium, underscore a unique activity and tolerability profile among VEGF TKI...
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of AVEO Pharmaceuticals, Inc. (“AVEO” or the “Company”) (NASDAQ: AVEO ) investors concerning the Company and its officers’ possible violations of federal securi...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...